Scientific oversight
Scientific leadership and independent review are required for each project. Project records will identify the accountable lead and reviewers before research execution.
ASTRANOVA RESEARCH & TRANSLATIONAL SCIENCES
Scientific questions. Responsible progress.
AstraNova’s research unit advances AI drug discovery, medicines security and pharmacovigilance through a focused scientific agenda, reproducible methods and responsible translation.
RESEARCH UNIT · LAUNCH PHASE
The unit is launching with three programmes and an initial project agenda. Programme activity, appointments, collaborations and completed outputs will be reported as they are established.
THREE CONNECTED PROGRAMMES
Discovery. Resilience.
Medicines safety.
Our operating model centres on a focused research office, specialist expertise and collaboration with appropriately qualified research partners.
01 / RESEARCH PROGRAMME
AI Drug Discovery
A computational research programme exploring drug repurposing and candidate prioritisation, with experimental validation undertaken through appropriately qualified research partners.
EXPLORE PROGRAMME ↗02 / RESEARCH PROGRAMMEMedicines Security & Resilience
An applied research programme examining supply dependencies, shortage risks and continuity considerations for a clearly defined group of medicines.
EXPLORE PROGRAMME ↗03 / RESEARCH PROGRAMMEPharmacovigilance & Medicines Safety
A research programme evaluating the quality of medicines-safety information and the responsible use of AI to assist safety-signal prioritisation.
EXPLORE PROGRAMME ↗RESEARCH GOVERNANCE
Credibility begins
before the first result.
Data and ethics
Establish lawful access, data permissions, privacy requirements and any applicable ethics approvals before research begins.
Reproducible methods
Define protocols, baselines, evaluation criteria, versioned analyses and documented limitations.
Responsible translation
Agree research ownership and publication terms. Separate exploratory findings from validated capabilities and operational decisions.
A DISCIPLINED START
Small initial scope.
Substantive outputs.
The initial agenda comprises one focused project per programme, with resources and specialist review agreed before research execution.
The research office model combines scientific leadership, computational research, medicines-security analysis and specialist pharmacovigilance input. Wet-laboratory validation requires appropriately qualified facilities and agreed partner arrangements. Confirmed collaborations will be announced with the partner’s permission.
The initial output agenda comprises protocols, reproducible analyses, evidence briefings and validation plans. Publications and performance claims will follow actual work and review.
DEVELOPMENT GATES
A programme built
on evidence of readiness.
Scope
Select the question, therapeutic or medicine scope, feasibility criteria and intended outputs.
Prepare
Secure leadership, budget, data access, review arrangements and collaboration terms.
Evaluate
Run the approved protocol, compare results and examine errors and limitations.
Translate
Seek independent review and decide whether publication, further validation or a commercial pathway is justified.
FIRST 90 DAYS · LAUNCH WORK PROGRAMME
From launch
to research readiness.
Define and organise
Assign project ownership, finalise the three research questions, record resource requirements and establish the protocol and collaboration registers.
Review and prepare
Complete literature and dataset reviews, assess permissions, agree methods and baselines, and identify suitable independent reviewers and validation partners.
Authorise and begin
Review readiness against each project’s governance gates. Begin approved analysis where conditions are met; record constraints and revised milestones where they are not.
This is the unit’s launch work programme, not a record of completed work or a guarantee of results within 90 days. Research execution depends on project-specific resources, permissions and review.
CLEAR RESPONSIBILITIES
Connected expertise. Defined roles.
AstraNova
Applied pharmaceutical research and responsible commercial translation, alongside the distribution business.
LUMIRAX
Technology support is assessed for defined research and operational workflows. Research applications require appropriate validation before findings or performance claims are relied upon.
Medicines Security Institute
A separate research and policy entity. Any collaboration would require disclosed relationships, agreed roles and protection of editorial independence. Formal collaborations will be identified when agreed.
Operational safety
Pharmacovigilance research is separate from any operational medicines-safety responsibilities, reporting arrangements or regulated service commitments.
RESEARCH OUTPUTS
Published work will follow completed research.
The unit is at launch phase; completed outputs have not yet been published. Publications will identify authorship, methods, dates, references, funding and conflicts, data limitations and review status. Research briefs will remain distinguishable from operational product claims.
RESEARCH COLLABORATION
Bring a question worth investigating.
We welcome research collaboration discussions with universities, computational researchers, medicines-security specialists and qualified safety scientists. Please do not send patient data or confidential datasets through the enquiry form.